CDK7 and head and neck squamous cell carcinoma: To further validate the therapeutic potential of CDK7 inhibition in a more advanced preclinical HNSCC model, we assessed the efficacy of samuraciclib and YKL-5-124 in a patient-derived xenograft (PDX) model (Fig. 6a).